4.89 -0.10 (-2.00%)
Pre-Market: 8:00AM EDT
|Bid||4.70 x 1100|
|Ask||4.90 x 900|
|Day's Range||4.90 - 5.44|
|52 Week Range||0.94 - 6.07|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 2, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.10|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 14) ABIOMED, Inc. (NASDAQ: ABMD ) AngioDynamics, Inc. (NASDAQ: ...
ArQule, Inc. (ARQL) today is presenting preliminary results from the Company’s Phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK) in patients with relapsed or refractory hematologic malignancies at the 23rd Congress of European Hematological Association (EHA) in Stockholm, Sweden. “Preliminary data from our Phase 1 dose escalation trial highlights the potential of ARQ 531 to become a new therapeutic option for patients with B-cell malignancies,” commented ArQule Chief Medical Officer and Head of Research and Development, Brian Schwartz, M.D. “There is a significant unmet need for patients with relapsed or refractory B-cell malignancies, in particular those with C481S-mediated resistance to irreversible BTK inhibitors such as ibrutinib.
ArQule, Inc. (ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at The JMP Securities Life Sciences Conference on June 21, 2018, at 10:30am EDT at the St. Regis in New York. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases.
In today's pre-market research, four stocks are presented for scanning: AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), Amgen Inc. (NASDAQ: AMGN), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and ArQule Inc. (NASDAQ: ARQL). Shares in Waltham, Massachusetts headquartered AMAG Pharmaceuticals Inc. saw a slight decline of 0.62%, ending Tuesday's trading session at $23.95.
ArQule, Inc. (NASDAQ: ARQL ) shares are up 367 percent year-over-year, but they’re still undervalued, according to Oppenheimer. The Rating Analyst Hartaj Singh initiated coverage on ArQule with an Outperform ...
The company announced that clinical data from the company-sponsored ARQ 531-101 Phase 1 dose escalation study in subjects with relapsed or refractory hematologic malignancies would be presented on June 15, 2018, at the EHA Congress in Stockholm, Sweden. Basilea will be responsible for all costs and expenses of development, manufacture, and commercialization in its territory.
NEW YORK, June 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Qudian ...
ArQule, Inc. (ARQL) today announced clinical data from the company-sponsored ARQ 531-101 Phase 1 dose escalation study in subjects with relapsed or refractory hematologic malignancies will be presented on June 15, 2018 at the EHA Congress in Stockholm, Sweden. ARQ 531 is an orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK).
ArQule, Inc. (ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at the Jefferies 2018 Healthcare Conference on June 7, 2018, at 3:00 p.m. ET at the Grand Hyatt, New York, New York. ArQule’s mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients.
ArQule, Inc. (ARQL) today announced two strategic additions to its executive team, appointing Dr. Marc Schegerin as senior vice president, corporate strategy, communication and finance, and Dr. Shirish Hirani as senior vice president, program management and product planning. “We are delighted to welcome both Marc and Shirish to ArQule’s executive team,” commented ArQule CEO, Paolo Pucci.
Merck's (MKGAF) Healthcare and Life Science segments to drive sales in Q1. However, operating expense is expected to be higher to support the launch of Bavencio and Mavenclad.
The most recent earnings release ArQule Inc’s (NASDAQ:ARQL) announced in December 2017 suggested company earnings became less negative compared to the previous year’s level as a result of recent tailwindsRead More...
On a per-share basis, the Burlington, Massachusetts-based company said it had a loss of 7 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
NEW YORK, NY / ACCESSWIRE / May 7, 2018 / ArQule, Inc. (NASDAQ: ARQL ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 7, 2018 at 9:00 AM Eastern Time. To listen to ...
After eking out a modest gain in the week ended April 27, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) pulled back this week amid some not-so-encouraging earnings reports and negative regulatory ...
ArQule, Inc. (ARQL) today announced it will report financial results for the first quarter of 2018 before the market opens on Monday, May 7, 2018. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general business update.
Stock Monitor: Hemispherx Biopharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free research report on ArQule, Inc. (NASDAQ: ARQL ). If ...
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Netflix, Inc. (NASDAQ: NFLX ) shares gained around ...
ArQule, Inc. today announced that it has entered into an exclusive license agreement with Basilea Pharmaceutica International Limited to develop and commercialize derazantinib, a pan-FGFR inhibitor in the US, EU, Japan and rest of the world excluding the People’s Republic of China, Hong Kong, Macau and Taiwan, where Sinovant Sciences Ltd., a Roivant Sciences Ltd.
Basel, Switzerland, April 17, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has entered into a license agreement with ArQule, Inc. (NASDAQ: ARQL) for its oncology drug candidate ...
ArQule, Inc. (NASDAQ:ARQL) is attracting a substantial amount of attention in the biotechnology sector as we head into the start of a fresh week of trading, with the company serving up a degree of insight into one of its lead investigative programs and markets responding positively to the development. So what happened? Well, for anybody […] The post ArQule, Inc. Is Moving On ASCO Release, Here’s Why. appeared first on Market Exclusive.